Provided by Tiger Fintech (Singapore) Pte. Ltd.

Longeveron Inc

1.61
+0.05003.21%
Post-market: 1.610.00000.00%16:11 EDT
Volume:134.08K
Turnover:213.04K
Market Cap:24.03M
PE:-0.62
High:1.61
Open:1.55
Low:1.54
Close:1.56
Loading ...

Company Profile

Company Name:
Longeveron Inc
Exchange:
NASDAQ
Establishment Date:
2014
Employees:
25
Office Location:
Life Science & Technology Park,Suite 520,1951 NW 7th Avenue,Miami,Florida,United States
Zip Code:
33136
Fax:
- -
Introduction:
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, a candidate in Phase 2a/b trials that is used for the treatment of alzheimer's disease, hypoplastic left heart syndrome, and aging-related frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.

Directors

Name
Position
Joshua M. Hare
Co-Founder, Chief Science Officer, Chairman and Director
Cathy Ross
Director
Donald M. Soffer
Director
Douglas Losordo
Director
Erin Borger
Director
Neil E. Hare
Director
Rock Soffer
Director

Shareholders

Name
Position
Geoff Green
Chief Executive Officer
Anthony Oliva
Senior Vice President of Scientific Affairs
James Clavijo
Chief Financial Officer and Treasurer
Joshua M. Hare
Co-Founder, Chief Science Officer, Chairman and Director
Lisa McClain Moss
Senior Director of Manufacturing
Paul Lehr
International Executive Director, General Counsel, and Secretary